Multifocal Castleman disease (MCD) is a rare lymphoproliferative disorder characterized by lymphoid hyperplasia and may be associated with human herpesvirus type 8 (HHV-8). The disease may present in various forms, the most common of which are the idiopathic form and the form associated with HHV-8 infection, which is more often observed in patients with HIV infection. Clinically, the disease may present with symptoms such as fever, night sweats, weight loss, and enlarged lymph nodes, which may lead to difficulty in diagnosis and treatment. The pathogenesis of the disease remains poorly understood, but it is believed that multiple activation of inflammatory systems and changes in the immune system play a key role in its development.
History of the disease and interesting historical facts
The first description of Castleman's disease dates back to 1956, when it was first diagnosed by South African physician Dr. Benjamin Castleman. Since then, the disease has been the subject of intense research, resulting in several clinical forms, such as a single node or a multifocal form. Interestingly, the typical clinical profile of patients with multifocal Castleman's disease includes middle-aged men, although cases have been reported in women and children.
In the 1990s, associations between MCD and HIV infection were established, leading to a new wave of research. In the last two decades, attention to the disease has increased, particularly with the advent of new therapeutic strategies and an understanding of its pathogenesis, which has made more targeted treatment possible. This highlights the multifaceted nature of the disease and the need for further study.
Epidemiology
According to the literature, multifocal Castleman disease is a rare disorder with an incidence of 1 to 5 cases per 100,000 population per year. The disorder is more common in people with HIV, especially in countries with a high prevalence of the virus. Most cases are found between the ages of 30 and 60, but cases of multifocal disease can also occur at younger ages. Studies have shown that MCD may be more common in men, although the incidence in women is also increasing. Genes and environmental factors may influence incidence, and some studies have found racial and ethnic differences in incidence.
Genetic predisposition to this disease
Currently, a number of genes and mutations that may be associated with the development of multifocal Castleman disease are being studied. One of the most studied genes is the gene encoding interleukin-6 (IL-6), which plays an important role in inflammatory and immune processes. Elevated levels of IL-6 have been recorded in most patients with MCD, indicating its possible involvement in the pathogenesis of the disease. Other associated genes include those responsible for the regulation of immune cells and inflammatory responses, such as genes encoding tumor necrosis factors (TNF). It is important to note that the presence of certain mutations is not a sufficient condition for the development of the disease, but can increase the risk of its occurrence in combination with other factors.
Risk factors for the development of this disease
Risk factors for developing multifocal Castleman disease include, but are not limited to, the following:
- Human herpes virus type 8 (HHV-8) infection;
- HIV infection;
- Age range from 30 to 60 years;
- Male gender;
- The presence of other immune system diseases, such as systemic lupus erythematosus;
- Some chemical exposures, such as exposure to carcinogens.
These factors may contribute to both the development of the disease and its progression. Further research is needed to determine the precise mechanisms that influence disease in specific populations.
Diagnosis of this disease
Diagnosis of multifocal Castleman disease is often challenging because the clinical picture can be similar to symptoms of other diseases. The main symptoms include:
- Fever of unknown etiology;
- Night sweats;
- Weight loss;
- swollen lymph nodes.
- Symptoms of anemia.
Laboratory tests include testing for inflammatory markers, particularly C-reactive protein (CRP) and IL-6, which can be significantly elevated in MCD. Radiologic imaging, such as CT and MRI, is used to visualize lymph node enlargement and other changes in the body. The differential diagnosis should include lymphomas, infectious diseases, systemic inflammatory processes, and other lymphoproliferative disorders. It is important to perform a comprehensive evaluation and collaborate with multiple specialties to confirm the diagnosis.
Treatment
Treatment of multifocal Castleman's disease is multidisciplinary and may include both conservative and surgical methods. The main approaches to treatment are as follows:
- Pharmacological treatment, including glucocorticoids and specific anti-inflammatory drugs;
- Immunotherapy, including drugs aimed at blocking IL-6;
- Surgical removal of enlarged lymph nodes in case of their compression or other complications;
- Radiation therapy in rare cases;
- Participation in clinical trials of new drugs.
Each case of MCD is individual, and the choice of new treatment depends on the clinical picture and the patient's condition.
List of medications used to treat this disease
Medications that may be used to treat multifocal Castleman disease include:
- Dexamethasone;
- Tocilizumab (anti-IL-6 antibody);
- Sulfasalazine;
- Anabrazol;
- Bortezomib.
The patient's response to therapy must be carefully monitored and, if necessary, the prescription adjusted.
Disease monitoring
Monitoring of multifocal Castleman disease involves regular physician visits, laboratory tests, and radiological examinations to assess the effectiveness of treatment and the patient's condition. Monitoring steps may include:
- Special preventive examinations to identify possible relapses;
- Assessment of IL-6 and other inflammatory markers;
- Referral for additional examinations if condition worsens.
The prognosis of MCD depends on the form of the disease, associated pathologies and the effectiveness of treatment. Complications may include infectious processes, shortening of life and deterioration of the quality of life of patients, which emphasizes the importance of monitoring and early intervention.
Age-related features of the disease
Multifocal Castleman disease may have different clinical manifestations depending on the patient's age. In children, the disease often has a more acute onset and may manifest itself with rapidly progressing symptoms. In adults, patients often observe a more chronic course with episodes of exacerbations. Elderly people may have milder forms of the disease, but with concomitant pathologies, the risk of complications increases. Therefore, the approach to diagnosis and treatment should be individualized depending on the patient's age category.
Questions and Answers
- What is multifocal Castleman disease? It is a rare lymphoproliferative disorder characterized by lymphoid tissue hyperplasia and potential association with human herpes virus type 8 (HHV-8).
- What are the main symptoms of MCD? The main symptoms include fever, night sweats, weight loss and swollen lymph nodes.
- How is this disease treated? Diagnosis is based on clinical examination, laboratory tests for inflammatory markers, and radiologic examinations to evaluate lymph nodes.
- How is multifocal Castleman disease treated? Treatment may include glucocorticoids, immunotherapy, and surgery if needed.
- What is the prognosis for multifocal Castleman disease? The prognosis depends on the form of the disease, the patient's condition and the adequacy of treatment; in the presence of relapses and complications, the quality of life can significantly decrease.
